search
Back to results

Ghrelin in Cystic Fibrosis (ghrelin)

Primary Purpose

Cystic Fibrosis

Status
Unknown status
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
ghrelin
Sponsored by
Papworth Hospital NHS Foundation Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Cystic Fibrosis focused on measuring Cystic fibrosis, Weight, Appetite, Ghrelin, Cystic fibrosis with low BMI

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Cystic fibrosis
  • BMI </=19 kg/m2

Exclusion Criteria:

  • Needle phobia
  • Pulmonary infection requiring intravenous antibiotics in the past 2 weeks-

Sites / Locations

  • Papworth Hospital NHs Foundation TrustRecruiting

Arms of the Study

Arm 1

Arm Type

Placebo Comparator

Arm Label

saline injections

Arm Description

Outcomes

Primary Outcome Measures

Appetite

Secondary Outcome Measures

weight

Full Information

First Posted
September 30, 2008
Last Updated
July 26, 2010
Sponsor
Papworth Hospital NHS Foundation Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT00763477
Brief Title
Ghrelin in Cystic Fibrosis
Acronym
ghrelin
Official Title
The Effect of Ghrelin on Appetite and Immune Function in Patients With Cystic Fibrosis
Study Type
Interventional

2. Study Status

Record Verification Date
July 2010
Overall Recruitment Status
Unknown status
Study Start Date
April 2010 (undefined)
Primary Completion Date
February 2011 (Anticipated)
Study Completion Date
April 2011 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Papworth Hospital NHS Foundation Trust

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Background to ghrelin Ghrelin is a naturally occurring hormone found in the blood which stimulates appetite. In healthy individuals, levels of ghrelin are high before a meal and falls afterwards. Previous studies have shown that giving ghrelin (by injection) to thin patients with renal failure and cancer increases their food intake. Furthermore, addition of ghrelin may also reduce inflammation within the body. Cystic Fibrosis (CF) is a genetic disease which frequently results in recurrent lung infections (leading to progressive inflammatory lung damage) and low body weight. Low body weight in CF is associated with increased lung infections, rapidly worsening lung function and a shortened life expectancy. The researchers postulate that administration of extra ghrelin to CF patients with low body weight may increase food intake and reduce lung inflammation. If successful, this study might identify ghrelin as a potential therapy for CF patients to improve nutrition, decrease lung inflammation and thereby improve survival.
Detailed Description
The purpose of this study is to investigate the role of a naturally occuring hormone called ghrelin on appetite, energy expenditure and immune function in patients with cystic fibrosis. Theoretical framework: Despite advances in the molecular understanding of the disease, life-expectancy in Cystic Fibrosis (CF) remains severely limited. Reduced body-weight is associated with increased inflammatory lung damage and is a major predictor of mortality in CF patients. Malnutrition is highly prevalent in the CF population and results from both poor food intake and excessive energy expenditure. A therapy which improves nutrition may therefore have a significant effect on the prognosis of this disease. Ghrelin is the only physiological circulating factor that is known to increase food intake. Administration of acylated ghrelin to humans increases both hunger and food intake and has been found to increase appetite in chronic disease states associated with anorexia and weight loss (such as cancer and chronic renal disease). From multiple animal and in vitro human studies, ghrelin also appears to have anti-inflammatory properties which would potentially benefit CF patients in whom a chronic inflammatory state promotes lung destruction, malnutrition and increases mortality. Ghrelin replacement may therefore improve nutrition and decrease the inflammatory burden in CF patients, leading to an improvement in life-expectancy. If ghrelin is identified as having an important pathophysiological role in CF it may lead to a future study of its efficacy as a therapeutic agent. Design Methodology: The study has three sections: a cross sectional study of the levels of blood metabolic signals in participants with cystic fibrosis and healthy controls. a laboratory study of the effect of ghrelin on immune cells extracted from the blood of participants with cystic fibrosis and healthy controls a cross-over interventional study of repeated ghrelin administration in malnourished cystic fibrosis patients

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cystic Fibrosis
Keywords
Cystic fibrosis, Weight, Appetite, Ghrelin, Cystic fibrosis with low BMI

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
saline injections
Arm Type
Placebo Comparator
Intervention Type
Biological
Intervention Name(s)
ghrelin
Intervention Description
subcutaneous injection
Primary Outcome Measure Information:
Title
Appetite
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
weight
Time Frame
4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Cystic fibrosis BMI </=19 kg/m2 Exclusion Criteria: Needle phobia Pulmonary infection requiring intravenous antibiotics in the past 2 weeks-
Facility Information:
Facility Name
Papworth Hospital NHs Foundation Trust
City
Cambridge
State/Province
Cambridgeshire
ZIP/Postal Code
CB23 3RE
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andres R Floto, BM BSc, PhD
Phone
01480 830541
Email
andres.floto@papworth.nhs.uk
First Name & Middle Initial & Last Name & Degree
Jane D Elliott, MPhil
Phone
01480 364495
First Name & Middle Initial & Last Name & Degree
Andres Floto, MB BChir, PhD, FRCP
First Name & Middle Initial & Last Name & Degree
Katie J Wynne, MB BChir, PhD, FRCP

12. IPD Sharing Statement

Learn more about this trial

Ghrelin in Cystic Fibrosis

We'll reach out to this number within 24 hrs